Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study

Robert, Sarah Anne; Ghani, Rohana Abdul; Shah, Shamsul Azhar; Chinna, Karuthan; Mohamud, Wan Nazaimoon Wan; Kamaruddin, Nor Azmi

doi:10.1016/j.orcp.2015.03.005

Cited by 57 publications

(37 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the short term, relative to IBT alone, both liraglutide‐treated groups reported larger improvements in dietary disinhibition, and Multicomponent had larger reductions in binge eating. The present findings are supported by a preclinical study that showed that liraglutide suppressed feeding behavior via inhibitory processes , as well as by a previous 12‐week pilot study that demonstrated the benefits of liraglutide on binge eating behaviors . Taken together, these findings suggest that the effects of liraglutide on satiety, disinhibition, and food reward may potentially be beneficial for reducing episodes of binge eating.…”

Section: Discussionsupporting

confidence: 85%

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Chao

Wadden

Walsh

et al. 2019

Obesity

View full text Add to dashboard Cite

Objective This exploratory analysis examined the effects of intensive behavioral therapy (IBT) for obesity (“IBT‐alone”), IBT plus liraglutide 3.0 mg/d (“IBT‐liraglutide”), and IBT plus liraglutide 3.0 mg/d plus 12 weeks of a portion‐controlled diet that provided 1,000 to 1,200 kcal/d (“Multicomponent”) on changes in food cravings, eating behaviors, and eating disorder psychopathology at 24 and 52 weeks post randomization. Methods Adults with obesity (mean age = 47.6 ± 11.8 years and BMI = 38.4 ± 4.9 kg/m2; 79.3% female; 54.0% non‐Hispanic white; 44.7% black) were randomized to IBT‐alone (n = 50), IBT‐liraglutide (n = 50), or Multicomponent (n = 50). Results At weeks 24 and 52, liraglutide‐treated groups reported significantly larger declines in weight concern relative to the IBT‐alone group. At week 24, compared with IBT‐alone, liraglutide‐treated groups reported significantly greater reductions in dietary disinhibition, global eating disorder psychopathology, and shape concern. The Multicomponent group had significantly greater reductions in binge eating at week 24 relative to the IBT‐alone group. However, differences among groups were no longer significant at week 52. Groups did not differ in total food cravings at week 24 or 52. Conclusions The combination of liraglutide and IBT was associated with greater short‐term improvements in dietary disinhibition, global eating disorder psychopathology, and shape concern than IBT alone.

show abstract

Section: Discussionsupporting

confidence: 85%

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Chao

Wadden

Walsh

et al. 2019

Obesity

View full text Add to dashboard Cite

show abstract

“…A small trial involving 44 obese binge-eaters aimed to evaluate the efficacy of liraglutide 1.8 mg daily for 12 weeks [26]. Subjects were randomized to receive liraglutide 1.8 mg plus diet and exercise or diet and exercise alone.…”

Section: Clinical Trialsmentioning

confidence: 99%

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Onge¹,

Miller²,

Motycka³

2016

FNS

View full text Add to dashboard Cite

Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as diabetes, hypertension, and hyperlipidemia, significantly increase one's risk of heart attack, stroke, and even death. Liraglutide, a medication originally used to treat diabetes, has been approved for the treatment of obesity. Clinical trials have shown significant improvements in body weight and body mass index (BMI) at a dose of up to 3.0 mg daily. The most common adverse effects are gastrointestinal in nature, however, these often subside with time. Safety concerns with regards to thyroid tumors and pancreatitis should be carefully considered prior to use of this agent. Liraglutide should be considered an additional tool in the treatment of obesity, especially in patients with concomitant diabetes.

show abstract

“…Liraglutide, a GLP-1 receptor agonist, is indicated both for type 2 diabetes at a dose of up to 1.8 mg daily as well as for obesity, with a recommended dose of 3 mg daily. Liraglutide has previously been reported to ameliorate binge-eating disorder in patients with obesity without diabetes in a 12-week study, showing 80% remission with liraglutide 1.8 mg daily versus 50% with cognitive behavioral therapy (13).…”

Section: Discussionmentioning

confidence: 98%

Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report

Perez-Cheron¹

2018

AACE Clinical Case Reports

View full text Add to dashboard Cite

Objective: Bulimia nervosa, an eating disorder characterized by recurrent binging and purging episodes, is frequently associated with depression. Conventional therapy with antidepressants and cognitive behavioral therapy has poor long-term success. Appetite-regulating gut hormones such as glucagon-like peptide 1 (GLP-1) may be implicated in the pathophysiology, and thus, GLP-1 receptor agonists may be an effective therapy.Methods: A 26-year-old patient with polycystic ovary syndrome (PCOS) on chronic metformin therapy, with reactive hypoglycemia, bulimia nervosa, and depression, unresponsive to antidepressants and psychotherapy, was given a trial of liraglutide 1.2 mg daily to control hunger and prolong satiety.

show abstract

Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study

Cited by 57 publications

References 9 publications

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report

Contact Info

Product

Resources

About

Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study

Cited by 57 publications

References 9 publications

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology

Liraglutide (Saxenda&lt;sup&gt;&#174;&lt;/sup&gt;) as a Treatment for Obesity

Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report

Contact Info

Product

Resources

About

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity